Search
Angiogenic Biomarkers (sFlt-1/PlGF) in Preeclampsia Management: Real-World Evidence and Case Studies
SMFM Pregnancy Meeting 2025 Symposium (1 hour)
Join leading maternal-fetal medicine specialists, Dr. Sarosh Rana and Dr. Padmashree Woodham, as they discuss the real-world implementation and significant benefits of the sFlt-1/PlGF biomarker test in optimizing preeclampsia management, assessing risk, and safely prolonging pregnancies.
Speakers
Sarosh Rana, MD, MPH, FACOG
Professor of Obstetrics and Gynecology Section Chief, Maternal-Fetal Medicine
Chief Obstetrical Transformation Officer
University of Chicago Medicine
Sarosh Rana, MD, MPH, FACOG
Professor of Maternal-Fetal Medicine MFM Fellowship Program Director Medical College of Georgia
Learning objectives
- Discuss implementation of the sFlt-1/PlGF biomarker test in clinical practice.
- Understand the significant benefits of the sFlt-1/PlGF biomarker test in preeclampsia management, as supported by real-world evidence.
- Explore the value of the sFlt-1/PlGF test in assessing the risk of developing severe preeclampsia within a two-week timeframe, and how it can effectively contribute to safely prolonging pregnancies.
- Demonstrate the biomarker test’s ability to optimize treatment decisions and provide more precise and effective management of preeclampsia, particularly in situations of uncertainty or non-specific laboratory results.
Interested in learning how to gain access to the PreClara Ratio for preeclampsia risk assessment?
Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.